Journal
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume 182, Issue 6, Pages 1483-1487Publisher
MOSBY-ELSEVIER
DOI: 10.1067/mob.2000.106846
Keywords
endometriosis; gonadotropin-releasing hormone agonist; gonadotropin-releasing hormone antagonist; pain; quality of life
Categories
Ask authors/readers for more resources
OBJECTIVE: The purpose of this study was a quantification of changes in endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy. STUDY DESIGN: One hundred twenty women with significant endometriosis-associated pain participated in a 1-month double-blind. randomized, placebo-controlled trial. Pain was measured at baseline and at 2 and 4 weeks with visual analog scales and the Endometriosis Symptom Severity score. Quality of life was measured with the SF-36 instrument. Group means and SEMs were calculated. Paired t tests were used after determination of data normality. RESULTS: Compared with placebo-treated control subjects women treated with gonadotropin-releasing hormone agonist had a statistically (P < .0001) and clinically significant temporary increase in pain and a concomitant decrease in quality of life. CONCLUSION: The stimulatory phase of gonadotropin-releasing hormone agonist therapy is associated with an increase in endometriosis-associated pain and a decrease in quality of life.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available